"… it’s appalling — that, at the same time as the United States was prosecuting Nazi doctors for crimes against humanity, the U.S. government was supporting research that placed human subjects at enormous risk.”
Does an "apology" suffice for criminal experimentation designed to cause harm?
"What’s gone on with the pharmaceutical industry is a physician arms race to buy off doctors…"
"The risk was greater for individuals prescribed atypical rather than conventional drugs."
Antipsychotic Drugs and Risk of Venous Thromboembolism: Nested Case-Control Study BMJ
Five weeks after publishing a grossly dis-informative front-page report by Gina Kolata about Alzheimer’s research,The New York Times published a lengthy three paragraph correction.
How many children in foster care serve as human guinea pigs in commercial drug trials?
According to a report by the Associated Press, the FDA has approved expanded use of Merck’s toxic antipsychotic drug, Saphris, for treating acute manic-depressive behavior in adults. Antipsychotics (neuroleptics) are a controversial class of drugs: Risperdal (approved in 1993), Zyprexa (1994), Seroquel (1997), Abilify (2002), and Saphris (2009). These drugs’…
The prescribed drugs transformed Kyle Warren from a rambunctious healthy child into a drooling, sedated, obese, “shell.”
"The current way that DSMBs are constituted and report has resulted in a loss of faith." NEJM
There is no evidence to indicate that children have been the beneficiaries of the Pediatric Exclusivity Provision of FDAMA (enacted in 1998): there is evidence that pharmaceutical companies have increased their profits from the legislation by at least $14 billion.
The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research.
"He was one of the most prolific investigators in the area of postoperative pain management. His fraud sets back our knowledge in the field tremendously.” Dr. Steve Shafer, the editor in chief of Anesthesia & Analgesia.
